Collaboration to investigate yeast beta-glucan growth opportunities within land animal feed

Biotec Pharmacon ASA’s subsidiary Biotec BetaGlucans has today signed an agreement with Ohly GmbH to investigate potential growth opportunities within the land animal feed area

Biotec BetaGlucans and its long-time partner Ohly GmbH (part of Associated British Foods plc) have today entered into an agreement to join forces towards the land animal feed area.  Purpose of the agreement is to develop the use of yeast beta-glucan within this particular market segment, based on the unique knowledge and capabilities of both companies. Target is to identify and develop growth opportunities within 18 months. Both companies will work together to ensure success in this exciting market.

“Ohly is one of our longest and most valued suppliers. By joining forces, we believe there is an excellent opportunity to further expand our mutual success story” says Biotec Pharmacon’s CEO Christian Jørgensen.

“Our yeast beta glucan product is produced from primary cultivated yeast and has demonstrated superior performance, and we are convinced that this will be of value to a broad range of farm animals” says Ohly’s Global Feed Health Platform Director, Mariët van der Werf.

Yeast beta-(1,3)/(1,6)-glucan – a major constituent of yeast cell walls – is a modulator of the immune system of animals. Beta-(1,3)/(1,6)-glucan from baker’s yeast is known to be one of the most potent immune modulating beta-glucans. Numerous scientific studies have shown that when ingested orally, yeast beta-glucan can stimulate the cells of the immune system (macrophages) thereby helping to prevent and overcome infections.